PT  - JOURNAL ARTICLE
AU  - Xianlin Duan
AU  - Ming Jiang
TI  - Analysis of Clinical Manifestations and Prognosis of 92 Cases with Non-Hodgkin's Lymphoma
AID  - 10.1007/s11805-008-0195-z
DP  - 2008 Jun 01
TA  - Chinese Journal of Clinical Oncology
PG  - 195--199
VI  - 5
IP  - 3
4099  - http://www.cancerbiomed.org/content/5/3/195.short
4100  - http://www.cancerbiomed.org/content/5/3/195.full
SO  - Cancer Biol Med2008 Jun 01; 5
AB  - OBJECTIVE To analyze the risk factors and influence of various treatments on the prognosis of non-Hodgkin’s lymphoma (NHL).METHODS Clinical data of 92 patients with NHL from our hospital were retrospectively reviewed. Kaplan-Meier statistics were used to analyze the differences in survival times of the patients receiving various treatments. Cox regression model was employed for analyzing the prognostic factors.RESULTS Among our patients, the 2 and 5-year disease-free survivals (DFS) were respectively 68% and 51%. The 5-year cancer-specific survival (CSS) was 55%. Mono-factorial analysis showed that the main independent prognostic factors included Ann Arbor Staging, B symptoms, lactate dehydrogenase (LDH), the international prognostic index (IPI) and age. Concerning the IPI, the 5-year CSS for the low-risk factors (0~1), lower-moderate risk (2), higher-moderate (3) and high-risk (4~5) were respectively 60%, 62%, 42% and 33%. Analysis of the prognoses, based on treatment of the patients with different stages, was as follows: the 5-year survival rates of the Stage-I and II patients, receiving surgery or chemotherapy alone, or a combined therapy, were respectively 19%, 72% and 68%, showing that the survival rates of the group with a combined therapy and the chemotherapy alone were superior to the group with surgery alone; the 5-year survival rates of the Stage-III and IV patients, receiving surgery or chemotherapy alone or a combined therapy, were respectively 50%, 35% and 60%, indicating that the survival rate of the group with a combined therapy was superior compared to the group with chemotherapy alone.CONCLUSION Long-term survival of non-Hodgkin’ s lymphoma patients is closely related with multiple factors. Rational detection and assessment of the risk factors may prolong the living time of the patients. Different methods of treatment can influence the patient’s prognosis. Correct evaluation of the prognostic factors, and rational and effective therapy can prolong the patient’s survival.